Pharmaceuticals News and Research

RSS

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

American Scientific Resources receives additional Bayer Healthcare order for Disintegrator Needle Destruction Device

American Scientific Resources, Inc., confirms today that it has received formal confirmation and payment advice for the additional purchase of its Disintegrator Needle Destruction Device from Bayer-Schering Pharmaceuticals.

18 Mar 2010

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller.

18 Mar 2010

Evaluating all Medicare plan options can reduce healthcare costs

Nearly 8 million former workers have disabilities so severe that they rely on Social Security Disability Insurance benefits, and an estimated 3.3 million more will apply for disability benefits this year. For these people and others suffering from serious conditions and disabilities, taking the right steps quickly to manage costs is essential for their financial and health well-being, according to Allsup, a nationwide provider of Social Security disability representation and Medicare plan selection services.

18 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second (FEV(1)).

18 Mar 2010

Acurox NDA: FDA schedules Advisory Committee meeting

Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.

18 Mar 2010

Actavis receives FDA marketing approval for Alprazolam ODT

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.

18 Mar 2010

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.

18 Mar 2010

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Executives from pharmaceutical companies and health care payer and provider organizations convened at the "Selling Pharmaceuticals in 2015" forum in Philadelphia to discuss mutually beneficial partnerships that, if implemented, could replace the traditional model of selling drugs on price, features and benefits with a new model that focuses on quantifying and communicating total value.

18 Mar 2010

Drugmakers are 'under-exposed' in emerging markets, report says

Growing markets for pharmaceuticals in China, Brazil, Russia and India are outpacing national markets in Europe and the U.S., but major drugmakers have been slow to expand in these markets and may lose opportunities, a new study finds, The New York Times reports. To put the shift in perspective, China will overtake both France and Germany next year in terms of drug spending, while Brazil will overtake Britain, according to the report by research firm IMS Health.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

"With Congress just days away from an expected vote, Democrats still hadn't settled on final language of the bill and until they do the Congressional Budget Office can't release an estimate for how much the complete package would cost." House Majority Leader Steny Hoyer (D., Md.) said yesterday that "he hoped Democratic leaders would be able to lock down final details soon.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

MiddleBrook Pharmaceuticals, DoctorDirectory.com enter into agreement to expand IncreaseRx promotion program

MiddleBrook Pharmaceuticals, Inc. today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner for MOXATAG (amoxicillin extended-release) Tablets, 775 mg, to expand its previously announced IncreaseRx® promotion program.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Pharmaceuticals News and Research

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

American Scientific Resources receives additional Bayer Healthcare order for Disintegrator Needle Destruction Device

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

Evaluating all Medicare plan options can reduce healthcare costs

Genes allowing opium poppy to make codeine and morphine discovered

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

Acurox NDA: FDA schedules Advisory Committee meeting

Actavis receives FDA marketing approval for Alprazolam ODT

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Drugmakers are 'under-exposed' in emerging markets, report says

Agendia to participate in groundbreaking clinical trial for breast cancer

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

MiddleBrook Pharmaceuticals, DoctorDirectory.com enter into agreement to expand IncreaseRx promotion program

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence